Leading the Way in Life Science Technologies

GEN Exclusives

More »
Readers Comments Back to Item »

BIO-Europe 2009 Day 3

2 Readers' Comments

Posted by: EBD Group

11/09/2009

As always, EBD Group appreciates GEN’s solid reporting from our events. To your closing point about moving BIO-Europe to a location in Eastern Europe, we are always interested in hearing from cities and regions that would like to host BIO-Europe, BIO-Europe Spring (and also, in Europe, EuroMedtech and BioEquity).

Our decision on where to hold an event is made on the basis of there being a relevant and thriving local biotech (or medtech) industry that is supportive of the event, a suitable venue (think of where to put all those partnering booths!) and the type financial package offered by the potential host.

We need to plan 2 to 3 years ahead, so the sooner we hear from prospective hosts the better we can evaluate their location.

Posted by: BIOtech Europe

11/09/2009

This is a good summary of some of the companies and innovations presented by executives at the BIO-Europe 2009 event. Light Sciences Oncology seem to have a very interesting business.
It would also be good to see a new venue selected, my company Liftstream would really like to participate in an event in Eastern Europe where there are new talent markets.

  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »